1. Home
  2. Companies
  3. AT1
  4. Material Events

Atomo Diagnostics (ASX:AT1) — Material Events

ASX:AT1 · 17 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Major 1 article Significant 12 articles Notable 4 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
12
Atomo Diagnostics Nearly Doubles Pascal Cassette Supply Deal Amid US Market SurgeMedium
Atomo Diagnostics boosts Pascal cassette supply deal with Lumos for FebriDx, potential revenues nearly double
21 Aug 2025 ·ASX Announcement ·85
Atomo Diagnostics Surges 121% Revenue, Expands Global Test PortfolioMedium
Atomo Diagnostics Q2 FY26 revenue surges 121%, secures key HIV and liver test orders, expands operations
28 Jan 2026 ·Quarterly Report ·85
Atomo Diagnostics Secures US Supply Deal and Boosts HIV Test Sales Amid Board RenewalMedium
Atomo Diagnostics advances US supply deal, HIV test sales surge, and secures A$2.6M capital in Q4 FY25
29 July 2025 ·Quarterly Activity Report ·85
Atomo Diagnostics Accelerates US Growth Following FebriDx FDA CLIA WaiverMedium
Atomo Diagnostics Q3 FY26: Strong Sales Growth, US Market Expansion, $3M Capital Raise
28 Apr 2026 ·Quarterly Activities and Cashflow Report ·85
Atomo Diagnostics Narrows Loss, Secures $3.13M Capital Raise and Major US Supply DealMedium
Atomo Diagnostics narrows loss, raises $3.13M, secures major US supply contract
29 Aug 2025 ·Appendix 4E Preliminary Final Report ·85
Atomo Scores US$410K Order as FebriDx Eyes US Market SurgeMedium
Atomo Diagnostics wins US$410K order from Lumos amid major US FebriDx distribution deal
7 Aug 2025 ·ASX Announcement ·85
Atomo Diagnostics Advances FDA Bid and Boosts Capital in Q1 FY26Medium
Atomo Diagnostics advances FDA submissions, secures new capital, and reports Q1 FY26 revenue of $680k
29 Oct 2025 ·Quarterly Activity Report ·85
Atomo Diagnostics Secures Exclusive Global License for Rapid Liver Function TestMedium
Atomo Diagnostics secures exclusive global license for novel rapid liver function test
20 Jan 2026 ·Licensing Agreement Announcement ·80
Atomo Diagnostics Secures $630k HIV Self-Test Order Backed by Government ProgramMedium
Atomo Diagnostics wins A$630k order for HIV Self-Tests supporting national government-funded program
6 Feb 2026 ·ASX Announcement ·75
Atomo Diagnostics Lands A$416K HIV Self-Test Order Backed by Global FundMedium
Atomo Diagnostics Secures A$416,000 HIV Self-Test Order Funded by Global Fund
30 Jan 2026 ·Contract Announcement ·75
Atomo Diagnostics Secures $502K HIV Self-Test Order for AfricaMedium
Atomo Diagnostics wins $502K HIV Self-Test order for African supply
15 Jan 2026 ·ASX Announcement ·75
Atomo Diagnostics Clarifies Disclosure Timing After Lumos FDA Waiver Approval and Capital RaiseMedium
Atomo Diagnostics confirms compliance with ASX disclosure rules following Lumos FDA CLIA waiver approval and capital raise
17 Apr 2026 ·ASX Aware Letter Response ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.